The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App 
Professionals >> Visit The Body PROThe Body en Espanol

What's New at The Body

HIV/AIDS News You Can Use

July 11, 2002

The Body's Extensive Coverage of The XIV International AIDS Conference

Visit The Body throughout the week and check up on the latest developments from Barcelona! Read coverage from our outstanding medical reporters, and tune in to audio and video feeds straight from the conference.

International AIDS Conference Top Stories

First-Line Therapy
Protease inhibitors are taking a big hit as first-line agents in the treatment of antiretroviral-naive patients. As Pablo Tebas, M.D. notes, the studies are finally catching up to clinical practice.

Starting Treatment
There's even more confirmation of the rationale for a more conservative approach to beginning antiretroviral therapy: Waiting until CD4+ cell counts consistently drop below 350, it seems, should be state-of-the-art care. Read Pablo Tebas, M.D.'s coverage for more details.

Recent data show that tenofovir may be even more effective as a first-line HIV treatment than as a treatment in people who have failed multiple drug regimens. Ben Young, M.D. covers.

Although all the potential uses for tenofovir are still being explored, one large clinic documented the results as it tested a variety of uses of the drug. Read Cal Cohen, M.D.'s coverage.

Liver Problems
Although there's anecdotal evidence that suggests people using NNRTIs are at a greater risk of developing liver problems, a recent study shows that the overall risk of serious liver injury is low in the real-world clinic population -- and is apparently independent of the type of antiviral treatment used. Ben Young, M.D. provides the details.

Drug Resistance
Twelve percent of newly infected, treatment-naive patients in New York State have some evidence of drug-resistant virus. This is a disturbingly high number, but not inconsistent with previous national reports of drug resistance in major metropolitan areas. Mark Holodniy, M.D. reports on resistance prevalence in New York State.

Lipodystrophy and Metabolic Disorders
Mark Holodniy, M.D., reviews the latest research on metabolic disorders related to HAART. His coverage includes a rundown of the basics, an examination of known disorders and their possible treatments, and a recap of one man's moving personal account of his battle with lipodystrophy.

Once again, study results reveal that directly observed antiretroviral therapy -- even with patients who have low CD4+ counts -- seems to be successful.

More Coverage from the Source
For news directly from the International AIDS Conference site, click here.

Also in Barcelona: Protests, Protests, Protests

In an effort to raise awareness about Coca-Cola's refusal to offer treatment to HIV-positive workers in developing countries, AIDS activists protested outside the International AIDS Conference conference center. Read more on this and other news in this update from AIDS Action.

For the second day in a row, an AIDS drug manufacturer's exhibition has been ransacked in protest by ACT-UP Paris.

Internationally, Staggering Infection Estimates, Almost No Access to Meds

A new report from the United Nations AIDS program states that at current infection rates, AIDS will kill 68 million people in the 45 most affected countries over the next 20 years.

More bad news: Less than 4 percent of those in need in the developing world have access to antiretroviral treatment and the epidemic is not declining in countries most affected.

In the U.S., Severe Lack of Awareness

The vast majority of young U.S. gay and bisexual men in a new study who were found to have HIV were unaware of their infection, according to a report presented at the XIV International AIDS Conference.

Web Highlights
A Selection of the Top HIV/AIDS Stories From Across the Internet

AIDS Crisis Is Like 9/11 Every Day in Africa
Excerpt from a recent sermon by an African reverend visiting the U.S.
From The Detroit Free Press (July 8, 2002)

Novel Class of Anti-AIDS Drugs Called a "Lifeline"
A closer look at just how T-20 and other entry inhibitors work
From MSNBC (July 8, 2002)

Widespread Infection From AIDS Virus Threatens to Destabilise African Nations
In Botswana, with its 40 percent infection rate, the situation could be especially dire
From The Independent (London) (July 8, 2002)

Call for Action, and Access, on AIDS
Leaders and activists clamor in Barcelona for universal access to drugs
From MSNBC (July 7, 2002)

Previous Update | Next Update
Back to The Body's HIV/AIDS News Updates main page